Lexaria Bioscience (LEXX) Free Cash Flow Growth (3y) (2013 - 2026)
Lexaria Bioscience (LEXX) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -1.95% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -20.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 21.16% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 45.09% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 80.69% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -23.92% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 8.92% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -4.45% |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | 2.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 2.90% |
| Feb 28, 2026 | -21.10% |
| Nov 30, 2025 | 8.05% |
| Aug 31, 2025 | -30.96% |
| May 31, 2025 | -41.47% |
| Feb 28, 2025 | -5.45% |
| Nov 30, 2024 | -31.53% |
| Aug 31, 2024 | -20.27% |
| May 31, 2024 | -3.06% |
| Feb 29, 2024 | 0.96% |
| Nov 30, 2023 | -13.44% |
| Aug 31, 2023 | -36.38% |
| May 31, 2023 | -38.62% |
| Feb 28, 2023 | -18.09% |
| Nov 30, 2022 | -31.62% |
| Aug 31, 2022 | -16.40% |
| May 31, 2022 | 0.80% |
| Feb 28, 2022 | -11.49% |
| Nov 30, 2021 | -20.71% |
| Aug 31, 2021 | -9.94% |